Similar to the in vivo results using the CRISPR system, we observed that cisplatin treatment significantly decreased tumor growth in shTREX1 tumors when compared with shCtrl groups or untreated shTREX1 tumors (Fig. 4H), suggesting that cytoplasmic dsDNA degradation by TREX1 contributes to the survival and growth of chemoresistant SCLC cells. Here, TREX1 is linked to neoplasm.